PNC Financial Services Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-21
| Closed | -$9 | – | 4965 |
|
|
2024
Q1 | $9 | Hold |
21
| – | – | ﹤0.01% | 4680 |
|
|
2023
Q4 | $16 | Hold |
21
| – | – | ﹤0.01% | 4601 |
|
|
2023
Q3 | $18 | Hold |
21
| – | – | ﹤0.01% | 4592 |
|
|
2023
Q2 | $39 | Hold |
21
| – | – | ﹤0.01% | 4710 |
|
|
2023
Q1 | $79 | Hold |
21
| – | – | ﹤0.01% | 4637 |
|
|
2022
Q4 | $81 | Hold |
21
| – | – | ﹤0.01% | 4706 |
|
|
2022
Q3 | $0 | Hold |
21
| – | – | ﹤0.01% | 4655 |
|
|
2022
Q2 | $0 | Hold |
21
| – | – | ﹤0.01% | 4781 |
|
|
2022
Q1 | $1K | Hold |
21
| – | – | ﹤0.01% | 4418 |
|
|
2021
Q4 | $1K | Hold |
21
| – | – | ﹤0.01% | 4350 |
|
|
2021
Q3 | $2K | Hold |
21
| – | – | ﹤0.01% | 4151 |
|
|
2021
Q2 | $2K | Buy |
+21
| New | +$2.32K | ﹤0.01% | 4064 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 4209 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 4268 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 4297 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 4302 |
|
|
2017
Q4 | – | Sell |
-50
| Closed | -$19.3K | – | 4265 |
|
|
2017
Q3 | $14K | Hold |
50
| – | – | ﹤0.01% | 3557 |
|
|
2017
Q2 | $13K | Hold |
50
| – | – | ﹤0.01% | 3498 |
|
|
2017
Q1 | $17K | Hold |
50
| – | – | ﹤0.01% | 3352 |
|
|
2016
Q4 | $30K | Sell |
50
-71
| -59% | -$75K | ﹤0.01% | 3066 |
|
|
2016
Q3 | $137K | Sell |
121
-8
| -6% | -$8.63K | ﹤0.01% | 2308 |
|
|
2016
Q2 | $141K | Sell |
129
-172
| -57% | -$216K | ﹤0.01% | 2294 |
|
|
2016
Q1 | $387K | Hold |
301
| – | – | ﹤0.01% | 1688 |
|
|
2015
Q4 | $740K | Buy |
301
+32
| +12% | +$49.1K | ﹤0.01% | 1334 |
|
|
2015
Q3 | $296K | Buy |
269
+96
| +55% | +$111K | ﹤0.01% | 1868 |
|
|
2015
Q2 | $174K | Hold |
173
| – | – | ﹤0.01% | 2319 |
|
|
2015
Q1 | $176K | Hold |
173
| – | – | ﹤0.01% | 2327 |
|
|
2014
Q4 | $576K | Sell |
173
-22
| -11% | -$67.4K | ﹤0.01% | 1483 |
|
|
2014
Q3 | $564K | Buy |
195
+22
| +13% | +$72.8K | ﹤0.01% | 1412 |
|
|
2014
Q2 | $656K | Buy |
173
+87
| +101% | +$328K | ﹤0.01% | 1279 |
|
|
2014
Q1 | $470K | Buy |
+86
| New | +$453K | ﹤0.01% | 1436 |
|
Other funds holding NBSE
PNC Financial Services Group's NBSE Position: Q2 2024 in Review
PNC Financial Services Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 21 shares — an estimated $9 sold.
PNC Financial Services Group first reported a position in NBSE in Q1 2014 and held it in 27 quarters. The position peaked at $740K in Q4 2015. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.
- PNC Financial Services Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- PNC Financial Services Group sold 21 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $9.
- PNC Financial Services Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 27 quarters.
- PNC Financial Services Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $740K in Q4 2015.
- 3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.
Based on PNC Financial Services Group's 13F filing for Q2 2024, filed 9 Aug 2024.